In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. 3601-3601
Abstract:
3601 Background: Quantitative assessment of tumor architecture changes may help to early identify non-responder patients and propose a tailored treatment strategy. Our objective was to build and validate a radiomics signature able to predict early the lack of response to chemotherapy including FOLFIFRI and bevacizumab using baseline and first evaluation CT and to compare it to the RECIST and morphological criteria. Methods: For 230 patients of PRODIGE 9 study and treated by FOLFIRI and bevacizumab, a computed analysis (CA) was performed on the dominant liver lesion (DLL) at baseline and 2 months post-chemotherapy. RECIST evaluation was performed at 2 and 6 months. The sum of the target liver lesions (STL), the density of the DLL, CA parameters and their changes rates were correlated with the 2-year survival status. A radiomics signature combining 3 parameters was built in one arm and validated in the second arm. Survival was estimated with the Kaplan-Meier method and compared with log-rank test. Results: The strongest predictive factors for 2-year survival status were decrease in STL(AUC = .69±.05[95%CI:.60-.77]), change rate in kurtosis(ssf = 0) (AUC = .66±.05[95%CI:.57-.74] ), and the baseline density of the DLL (AUC = .68±.05[95%CI:.59-.77]). Using multivariate analysis, predictive factors of 2-year survival status were the decrease in STL 〉 15%(HR = 1.92, P= .002), the increase in kurtosis value(ssf = 0) 〉 93% (HR = 2.16, P= .001), and baseline DLL 〉 64.3UH (HR = 1.70, P= .02). Then, the SPECTRA-score was built by according 1 point for each of the 3 criteria. Patients with a SPECTRA-score 〉 1 had a lower overall survival in the training ( P= .001) and in the validation cohort ( P= .002). Non-response according to RECIST at 6 months had the same prognostic value as SPECTRA-score 〉 1 at 2 months. Conclusions: A radiomics signature combining STL, density and CA on baseline and first evaluation CT is be able to predict which patient will have a poor outcome with same performances than standard evaluation with RECIST1.1 at 6 months in mCRC patients. Clinical trial information: NCT00952029.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2017.35.15_suppl.3601
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2017
detail.hit.zdb_id:
2005181-5
